# Immunic, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Immunic, Inc). ## Overview Immunic, Inc. is a late-stage biotechnology company developing oral small-molecule therapies for chronic inflammatory, autoimmune, neurologic, and gastrointestinal diseases. Its lead program, vidofludimus calcium (IMU-838), is in Phase 3 development for relapsing multiple sclerosis, while IMU-856 and IMU-381 target gastrointestinal and autoimmune indications. ## Products & services • Vidofludimus calcium (IMU-838) for multiple sclerosis and UC • IMU-856 for bowel epithelium and intestinal barrier repair • IMU-381 next-generation Nurr1-based molecule • Oral small-molecule immunology pipeline • Clinical development programs for neurologic and GI diseases - **Lead clinical asset: IMU-838** (45%) — Phase 3 oral therapy for relapsing multiple sclerosis with prior activity in MS and ulcerative colitis studies. - **Gastrointestinal program: IMU-856** (25%) — Oral program aimed at regenerating bowel epithelium and restoring intestinal barrier function. - **Preclinical pipeline: IMU-381** (15%) — Next-generation molecules leveraging the Nurr1 platform for GI and autoimmune diseases. - **Platform and discovery capabilities** (15%) — Internal research, translational work, and clinical development infrastructure supporting the pipeline. - Vidofludimus calcium (IMU-838) for relapsing multiple sclerosis - IMU-838 clinical development in RRMS, PMS and ulcerative colitis - IMU-856 for celiac disease, IBD, GvHD and related GI disorders - IMU-381 preclinical program for gastrointestinal and autoimmune diseases - Oral small-molecule immunology platform and pipeline development ## Customers Immunic does not sell commercial products today; its “customers” are primarily patients, physicians, and regulators that determine whether its drug candidates can advance and eventually be approved. The company also depends on clinical trial sites, contract research organizations, and development partners to execute studies across its target indications. - **Neurology patients** (primary) — Patients with relapsing multiple sclerosis and related neurologic disease who are the target population for IMU-838. - **Gastroenterology patients** (primary) — Patients with ulcerative colitis, celiac disease, IBD, and GvHD targeted by IMU-856 and IMU-381. - **Healthcare professionals** (secondary) — Neurologists, gastroenterologists, and key opinion leaders who assess clinical data and influence future adoption. - **Regulators and payors** (secondary) — FDA, EMA, and reimbursement stakeholders that determine approval, labeling, and market access. - **Clinical development partners** (secondary) — CROs, investigators, and trial sites that buy services from the company indirectly through study execution. - Patients with relapsing multiple sclerosis and other autoimmune diseases - Patients with ulcerative colitis and broader gastrointestinal disorders - Physicians and key opinion leaders who influence trial adoption and future use - Regulators and payors that determine approval and reimbursement pathways - CROs, trial sites, and development partners that enable clinical execution ## Geography Immunic is headquartered in New York City, but its main operations are in Gräfelfing near Munich, Germany, making it operationally transatlantic. The company’s clinical development footprint is tied to major markets for MS and gastrointestinal disease, and its foreign operations expose it to euro-denominated costs and currency translation effects. - Headquartered in New York City - Main operations in Gräfelfing near Munich, Germany - German subsidiary is central to development and operations - Foreign currency exposure from euro-functional operations - Clinical programs are designed for major U.S. and European markets ## Strategy Immunic’s strategy is to advance its oral immunology pipeline through late-stage clinical proof-of-concept, with IMU-838 as the lead value driver. The company is also broadening optionality by developing IMU-856 and IMU-381 for adjacent gastrointestinal and autoimmune indications, while preserving capital through a focused development model. - **Complete late-stage development of IMU-838** (short-term) — Phase 3 success is the main path to regulatory approval and future commercialization. - **Expand pipeline optionality in GI disease** (medium-term) — IMU-856 and IMU-381 diversify the company beyond a single lead asset and broaden addressable markets. - **Preserve capital and extend runway** (short-term) — As a clinical-stage company with no product revenue, financing discipline is essential to keep programs moving. - Advance IMU-838 through Phase 3 for relapsing multiple sclerosis - Build clinical evidence in ulcerative colitis and other inflammatory diseases - Develop IMU-856 for GI barrier repair and broader disease applicability - Progress IMU-381 as a next-generation follow-on molecule - Use oral small-molecule differentiation to target chronic disease convenience ## Risks Immunic is a clinical-stage biotech with no product sales, so its value depends on successful trial outcomes, regulatory approvals, and access to capital. The company also faces execution risk from complex, multi-site clinical programs, foreign-currency exposure from its German operations, and the possibility that its candidates may not achieve market acceptance even if approved. - **Clinical development failure** [critical] — The company’s lead assets are still in development, so negative trial data could eliminate or delay commercialization opportunities. - **Financing and dilution risk** [high] — The company has no product sales and will require substantial additional capital to fund trials and operations. - **Regulatory and market acceptance risk** [high] — Even successful trials may not translate into approval, reimbursement, or physician adoption. - **Operational and trial execution risk** [medium] — Multi-country clinical programs depend on CROs, sites, enrollment, and supply continuity. - **Foreign exchange risk** [medium] — German operations use the euro, creating translation and transaction exposure versus U.S. reporting currency. - No product revenue and no guarantee of future commercialization - Clinical trial failure or delays could materially impair pipeline value - Need for additional financing may dilute shareholders - Regulatory approval risk across MS and GI indications - Foreign exchange and cross-border operating complexity ## Accounting The key accounting issues are typical for a development-stage biotech: expense recognition for R&D, valuation of lease and contractual obligations, and judgment around contingent milestone/royalty arrangements. Foreign currency translation is also important because the German subsidiary uses the euro, while the company reports in U.S. dollars. - **Research and development expense recognition** — Affects operating loss and cash burn - **Contingent milestone and royalty obligations** — Potential future liabilities and expense recognition - **Operating lease accounting** — Affects balance sheet leverage and fixed obligations - **Foreign currency translation** — Translation gains/losses in other comprehensive income - R&D expense timing drives reported losses and reflects trial intensity - Milestone and royalty obligations under licensing agreements are contingent - Operating lease accounting affects balance sheet liabilities and cash commitments - Foreign currency translation affects equity and reported results - No revenue recognition complexity today because there are no product sales --- *Last updated: 2026-09-24T12:31:06.091999+00:00*